

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

## Nanoscale enzymatic compartments in tandem support cascade reactions in vitro

Journal:	<i>Biomacromolecules</i>
Manuscript ID	bm-2018-01019w.R1
Manuscript Type:	Article
Date Submitted by the Author:	31-Aug-2018
Complete List of Authors:	Belluati, Andrea; Universitat Basel, Departement Chemie Craciun, Ioana; Universitat Basel, Departement Chemie Liu, Juan; University of Basel Palivan, Cornelia; University of Basel, Chemistry Department

SCHOLARONE™  
Manuscripts

# 1 Nanoscale enzymatic compartments in tandem 2 support cascade reactions *in vitro*

3 *Andrea Belluati<sup>1</sup>, Ioana Craciun<sup>1</sup>, Juan Liu<sup>1</sup>, Cornelia G. Palivan<sup>1\*</sup>*

4 <sup>1</sup>Department of Chemistry, University of Basel, Mattenstrasse 24a, CH-4058 Basel

## 6 KEYWORDS

7 Catalytic compartment, polymersome, cascade reaction, *in vitro*, gout

## 9 ABSTRACT

10 Compartmentalization at the nanoscale is fundamental in nature, where the spatial segregation of  
11 biochemical reactions within cells ensures optimal conditions for regulating metabolic pathways.  
12 Here, we present a nature inspired approach to engineer enzymatic cascade reactions taking place  
13 between separate vesicular nanocompartments (polymersomes), each containing one enzyme  
14 type. We propose by the selected combination of enzymes, an efficient solution to detoxify the  
15 harmful effect of uric acid and prevent the accumulation of the derived H<sub>2</sub>O<sub>2</sub>, both being  
16 associated with various pathological conditions (e.g. gout and oxidative stress). Fungal uricase  
17 and horseradish peroxidase combined to act in tandem, were separately encapsulated within  
18 nanocompartments, equipped with channel porins as gates to allow passage of substrates and  
19 products from each step of the reaction. We established the molecular factors affecting the  
20 efficiency of the overall reaction, and the protective role of the compartments. Interestingly, the

1  
2  
3 21 cascade reaction between separate nanocompartments was as efficient as for free enzymes in  
4  
5 22 complex media, such as human serum. The nanocompartments were non-toxic towards cells and  
6  
7  
8 23 more importantly, addition of the tandem catalytic nanocompartments to cells exposed to uric  
9  
10 24 acid provided simultaneous detoxification of uric acid and the H<sub>2</sub>O<sub>2</sub>. Such catalytic  
11  
12 25 nanocompartments can be used as a platform for understanding fundamental factors affecting  
13  
14 26 intra-cellular communication and introduce non-native metabolic reactions into living systems  
15  
16  
17 27 for therapeutic applications.  
18  
19  
20  
21 28  
22  
23

## 24 29 **Introduction**

26  
27  
28 30 In nature, various enzymatic reactions occur in confined environments where substrates are  
29  
30 31 channeled in between enzymes, or signaling molecules are released and travel between  
31  
32 32 compartments<sup>1</sup> serving to isolate reactive intermediates, concentrate substrates in a specific  
33  
34 33 region or fine tune reaction pathways.<sup>2</sup> Inspired by nature, significant efforts have been made to  
35  
36 34 confine enzymes within nanocompartments, such as protein cages, lipid/polymer based  
37  
38 35 compartments and layer by layer capsules, resulting in enzymatic compartments.<sup>1, 3-4</sup> Enzymatic  
39  
40 36 compartments are of particular interest as they offer a protective environment that increases the  
41  
42 37 life-time of the encapsulated enzymes, essential for applications.<sup>5-6</sup> In this respect, a particularly  
43  
44 38 appealing class of compartments are polymersomes generated by self-assembly of amphiphilic  
45  
46 39 copolymers, as their membrane is more stable than the lipid membrane of liposomes, while  
47  
48 40 maintaining biocompatibility if the chemical nature of the copolymer is appropriately selected.<sup>7</sup>  
49  
50  
51 41 A key aspect to allow the enzymatic reaction to take place *in situ*, inside the cavity of  
52  
53 42 polymersomes, is to render their membrane permeable thus enabling an exchange of substrates  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 43 and products with their surroundings. Various approaches have been reported: i) using inherently  
4  
5 44 porous polymersomes,<sup>8-9</sup> ii) using an external stimulus, such as pH, or by addition of a chemical  
6  
7 45 agent to render the membrane permeable,<sup>10-11</sup> and iii) inserting biopores or membrane proteins in  
8  
9  
10 46 the membrane.<sup>12-13</sup>

11  
12  
13 47 Cascade reactions reported within nanocompartments mainly involve encapsulation of one type  
14  
15 48 of enzyme and providing the second enzyme free in the surrounding medium.<sup>6, 14</sup> However, if  
16  
17 49 one partner of the cascade reaction is free in solution it might be degraded, resulting in a  
18  
19  
20 50 decrease or even termination of the overall reaction. Co-encapsulating enzymes within the same  
21  
22 51 nanocompartment solves this issue, but only a low co-encapsulation efficiency can be obtained  
23  
24  
25 52 due to the statistic process of formation of multi-enzyme-loaded polymersomes.<sup>7</sup>



26  
27  
28 53 A higher encapsulation efficiency of different enzymes can be achieved by linking the two  
29  
30 54 enzymes together prior to encapsulation, using micrometer-sized compartments or the formation  
31  
32 55 of compartments within compartments where small compartments and free enzymes are  
33  
34  
35 56 encapsulated inside micrometer-size compartments.<sup>9, 15-18</sup> Both binding the enzymes in one  
36  
37 57 complex and the approach of compartments within compartments, which uses organic solvents  
38  
39 58 and emulsions, have the disadvantage of hindering the catalytic activity of the enzymes thus  
40  
41  
42 59 decreasing the efficiency or blocking the reaction.

43  
44 60 One approach, which allows for modularity while preserving the enzymes involved in the  
45  
46 61 cascade reaction, is to design catalytic compartments working in tandem.<sup>7</sup> However, there are  
47  
48 62 only very few examples of catalytic nanocompartments (CNCs) working in tandem<sup>8, 10, 19-20</sup> and,  
49  
50  
51 63 to the best of our knowledge, very few polymeric nanocompartments were evaluated in a more  
52  
53 64 complex medium or *in vitro*.<sup>21</sup> In addition, the kinetics of the cascade reactions in separate  
54  
55  
56 65 compartments and the molecular factors affecting them were not investigated to determine

1  
2  
3 66 whether such CNCs still function in a more complex medium than buffers or to propose a  
4  
5 67 therapeutically relevant solution.  
6

7  
8 68 Here, we present a bio-inspired approach to engineer CNCs working in tandem and propose, by  
9  
10 69 an appropriate selection of the enzymes, an efficient solution to detoxify the harmful effect of  
11  
12 70 uric acid and  $H_2O_2$ , associated with various pathologic conditions (e.g. gout and oxidative  
13  
14 71 stress). Both gout and oxidative stress are known to induce severe health problems, associated  
15  
16 72 with an increase in medical costs estimated to be above \$6 billion per year in the US.<sup>22</sup> We used  
17  
18 73 an amphiphilic block copolymer poly(2-methyloxazoline)-*block*-poly(dimethylsiloxane)-*block*-  
19  
20 74 poly(2-methyloxazoline) (PMOXA<sub>6</sub>-PDMS<sub>44</sub>-PMOXA<sub>6</sub>) for the formation of the  
21  
22 75 nanocompartments,<sup>23</sup> and their membrane was rendered permeable by insertion of the bacterial  
23  
24 76 porin Outer membrane protein F (OmpF).<sup>24</sup> The role of the polymersomes is to protect the  
25  
26 77 encapsulated enzymes in order to prolong their stability, as a crucial step towards translational  
27  
28 78 applications, as is intended by our selected enzymatic reaction. We selected as enzymes for the  
29  
30 79 cascade reaction uricase (UOX) and horseradish peroxidase (HRP), which uses  $H_2O_2$  produced  
31  
32 80 by UOX, as the substrate to initiate the second reaction (Scheme 1).<sup>25-27</sup> This non-native  
33  
34 81 combination of enzymes serves to sequentially decrease the concentration of uric acid and  
35  
36 82 prevent the accumulation of  $H_2O_2$ , derived from the reaction of uric acid degradation, thus  
37  
38 83 resulting in a dual therapeutic approach. While previous reports on cascade reactions between  
39  
40 84 nanocompartments focused on the feasibility of model reactions,<sup>20</sup> here we go one step further to  
41  
42 85 understand the molecular factors associated with the cascade reaction between separate  
43  
44 86 compartments and to optimize their overall function. Next, we investigate their ability to  
45  
46 87 function at increasing distances to mimic intra- and intercellular bio-distances as well as in  
47  
48 88 human serum, prior to applying them to decrease uric acid and the accumulation of  $H_2O_2$ , from  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

the cellular milieu to advance their therapeutic application. Our approach opens the avenue to combine different enzymes inside separate nanocompartments to obtain complex, novel-to-nature enzymatic pathways with high potential in diagnostics and therapeutics.



**Scheme 1.** Schematic representation of catalytic nanocompartments (OmpF: green rectangle) working in tandem and detailed cascade reaction mediated by a combination of uricase (UOX, red triangles) and horseradish peroxidase (HRP, blue hexagons). The oxidation of uric acid results in formation of 5-hydroxyisourate and hydrogen peroxide. The latter is a co-substrate for HRP in presence of substrate Amplex Ultra Red, AR. The final product, resorufin, can be monitored by fluorescence spectroscopy.

## Materials

Dulbecco's Modified Eagle Medium with 4.5 g L<sup>-1</sup> D-Glucose (DMEM-GlutaMax) was purchased from Gibco life technologies. Fetal calf serum (FCS) was purchased from BioConcept. CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS) was purchased from Promega. The triblock copolymer PMOXA<sub>6</sub>-PDMS<sub>44</sub>-PMOXA<sub>6</sub> was kindly

1  
2  
3 103 provided by Prof. W. Meier, the University of Basel.<sup>23</sup> All other reagents and enzymes were  
4  
5 104 purchased from Sigma-Aldrich unless otherwise specified.  
6  
7

## 8 105 **Methods**

### 9 10 11 106 *OmpF expression and extraction*

12  
13  
14  
15 107 Wild-type OmpF was obtained according to a previously reported protocol,<sup>28</sup> with a few  
16  
17 108 modifications: bacteria was grown at 30 °C for 6 hours on Terrific Broth (TB) (Difco, USA) and  
18  
19 109 all ultracentrifugations were performed at room temperature (RT).  
20  
21

### 22 110 *Preparation of catalytic nanocompartments*

23  
24  
25  
26 111 All CNCs were prepared at RT using the triblock copolymer PMOXA<sub>6</sub>-PDMS<sub>44</sub>-PMOXA<sub>6</sub>  
27  
28 112 (obtained according to a previously reported procedure<sup>23</sup>) and wild-type OmpF, via the film  
29  
30 113 rehydration technique. Films were rehydrated to a final polymer concentration of 4 mg mL<sup>-1</sup> with  
31  
32 114 0.25 mg of UOX or HRP in PBS (pH 7) and 50 µl of previously dialyzed OmpF (60 µg mL<sup>-1</sup>  
33  
34 115 final concentration) or an equivalent volume of dialyzed octyl glucopyranoside, OG (Anatrace,  
35  
36 116 USA) 3% for the non-permeabilized CNCs. Samples were extruded through an Avanti mini-  
37  
38 117 extruder (Avanti Polar Lipids, USA) with a 200 nm pore diameter polycarbonate membrane (11  
39  
40 118 times). Non-encapsulated enzyme was removed through size exclusion chromatography (SEC)  
41  
42 119 (Sephacrose 4B column; 30 cm length).  
43  
44  
45  
46

47 120

### 48 49 121 *Catalytic nanocompartment characterization — Static and Dynamic light scattering*

50  
51 122 Light scattering (LS) experiments were performed at 25 °C, using an ALV/CGS-8F goniometer  
52  
53 123 (Langen/Hessen, Germany) equipped with a frequency-doubled He-Ne laser (LS instruments, λ  
54  
55  
56  
57  
58  
59  
60

124 = 633). Static light scattering (SLS) was performed in 5° steps between 50° and 135° and  
 125 analyzed with Zimm plot software (LS Instruments). Dynamic light scattering (DLS) was  
 126 performed at 90° and analyzed through nonlinear decay-time analysis supported by cumulant fit.

127  
 128 *Catalytic nanocompartment characterization — Transmission electron microscopy (TEM)*

129 CNC suspensions in PBS at 0.25 mg mL<sup>-1</sup> were deposited on glow-discharged carbon grids  
 130 (Quantifoil, Germany) stained with 1.5% uranyl acetate solution and deposited on carbon-coated  
 131 copper grids. A transmission electron microscope (Philips Morgagni 268D) at 293 K was used.

132  
 133 *Catalytic nanocompartment characterization — Fluorescence correlation spectroscopy*

134 Vesicles were labeled with BODIPY 630/650 SE (Thermo Fisher Scientific, USA) 100 nM.  
 135 All measurements were carried out using an LSM 880 confocal laser microscope (Carl Zeiss,  
 136 Germany) with a 40x, 1.2 water immersion C-Apochromat objective lens. Measurements were  
 137 performed at RT using a sample volume of 20 μL on a 22x50 mm glass slide. A HeNe laser at  
 138 633 nm was used for excitation of the BODIPY fluorophore, at 1% attenuation and pinhole 62  
 139 μm. The fluorescence signal was measured in real time and the autocorrelation function was  
 140 calculated by the software calculator QuickFit 3.0.<sup>29</sup> Measurements were recorded over 5 s and  
 141 each measurement was repeated 30 times. Experimental auto correlation curves were fitted using  
 142 a two-component model including triplet state:

$$G(\tau) = 1 + \left(1 + \frac{T}{1-T} e^{-\frac{\tau}{\tau_{trip}}}\right) \frac{1}{N} \left( \frac{f_1}{1 + \frac{\tau}{\tau_{D1}} \sqrt{1 + R^2 \frac{\tau}{\tau_{D1}}}} + \frac{f_2}{1 + \frac{\tau}{\tau_{D2}} \sqrt{1 + R^2 \frac{\tau}{\tau_{D2}}}} \right)$$

143  $f_1$  and  $f_2$  are respectively the fraction of the particles of the corresponding component 1 (dye) or 2  
 144 (vesicles),  $\tau_{D1}$  represents the diffusion time of the dye and  $\tau_{D2}$  the diffusion time of the vesicles,  $T$



1  
2  
3 145 the fraction of fluorophores in triplet state with triplet time  $\tau_{\text{trip}}$ ,  $N$  is the number of particles and  
4  
5 146  $R$  the structural parameter, fixed at 5, according to the guidelines from Zeiss. The  $\tau_{\text{trip}}$  and  $\tau_{\text{D}}$  of  
6  
7 147 free dye were determined independently, and subsequently fixed in the fitting procedure for dye-  
8  
9 148 interacting vesicles. The confocal volume of 1 fL, was obtained by a calibration with free  
10  
11 149 BODIPY and was necessary to determine the concentration of fluorescent particles (knowing the  
12  
13 150 number of particles detected in the volume).  
14  
15  
16  
17  
18 151

### 19 20 152 *Enzyme quantification*

21  
22 153 The non-encapsulated enzyme fraction was recovered via SEC and the enhanced Pierce™  
23  
24 154 Bicinchonnic Acid (BCA) assay was performed according to the supplier's protocol (Thermo  
25  
26 155 Fisher Scientific, USA); instead of the BSA standards, both UOX (35 U mg<sup>-1</sup>) and HRP (300 U  
27  
28 156 mg<sup>-1</sup>) calibration curves were prepared for the quantification of the respective samples. The  
29  
30 157 amount of un-encapsulated protein was multiplied by the volume recovered from the column and  
31  
32 158 then subtracted from the amount initially added to the rehydration solution, yielding the total  
33  
34 159 amount of enzymes within the vesicles, divided by the volume of the vesicle (first fraction), *i.e.*  
35  
36 160 the final concentration of the protein. This was performed on samples with no inserted OmpF,  
37  
38 161 because the presence of the hydrophobic porin is not expected to influence the encapsulation  
39  
40 162 efficiency of hydrophilic enzymes. The number of enzyme molecules was then divided by the  
41  
42 163 number of vesicles, obtaining the number of enzymes per vesicle.  
43  
44  
45  
46  
47  
48 164

### 49 50 165 *Enzyme activity and kinetics*

51  
52 166 Kinetic parameters were calculated using the Michaelis-Menten model:

$$v = \frac{V_{\text{max}}[S]_0}{K_M + [S]_0}$$

$$k_{cat} = \frac{V_{max}}{[E]_0}$$

1  
2  
3  
4  
5  
6 167 Where  $v$  is the velocity of the enzyme,  $V_{max}$  is the maximum velocity at saturating concentration,  
7  
8 168  $[S]_0$  is initial the concentration of the substrate  $S$ ,  $K_M$  is the Michaelis-Menten constant.  $k_{cat}$  is the  
9  
10 169 turnover number, the number of chemical conversions per second,  $[E]_0$  is the concentration of  
11  
12 170 catalytic sites (both for UOX and HRP it is equivalent with the concentration of enzyme).

13  
14  
15 171 In all experiments involving a cascade reaction, UOX was added in excess to HRP, to partially  
16  
17 172 compensate for the former enzyme's lower activity, so that the ratio between production (from  
18  
19 173 UOX, 35 U mg<sup>-1</sup>) and consumption (from HRP, 350 U mg<sup>-1</sup>) of hydrogen peroxide would not be  
20  
21 174 the limiting factor. All enzymatic measurements were performed using a Spectramax M5  
22  
23 175 microplate reader (Molecular Devices, USA), in a in a 96-well, flat bottomed UV-transparent  
24  
25 176 plate (Corning, USA) for uric acid absorbance (290 nm) or in a black plate (Thermo Fisher  
26  
27 177 Scientific) for resorufin fluorescence (excitation 570 nm / emission 595 nm). The final volume in  
28  
29 178 each well was of 200 μL in PBS. UOX concentration was increased ten-fold in cascade reaction  
30  
31 179 experiments, to counter the slower native activity per weight of the enzyme, compared to the  
32  
33 180 downstream enzyme HRP. Both uric acid consumption and resorufin production were quantified  
34  
35 181 by means of calibration curves ( $R^2 > 0.9$  for both curves). Each experiment was performed in  
36  
37 182 triplicate and data was collected over 15 minutes (10 for the measurement of kinetic parameters).  
38  
39  
40  
41  
42

43 183

#### 44 184 *UOX kinetics*

45  
46 185 UOX or UOX-loaded CNCs (final concentration of 3 μg mL<sup>-1</sup>) were incubated in presence of  
47  
48 186 increasing concentrations of the substrate uric acid (25, 100, 200, 400 and 800 μM) and the  
49  
50 187 initial velocity of the enzymatic reaction was determined. The consumption of uric acid was  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 188 monitored and the data fitted with Graphpad Prism 7 software, obtaining  $K_M$ ,  $V_{max}$  and  $k_{cat}$   
4  
5 189 values.  
6  
7

8 190

9  
10 191 *HRP kinetics*

11  
12 192 HRP or HRP-loaded CNCs (final concentration of  $3 \mu\text{g mL}^{-1}$ ) were incubated in the presence of  
13  
14 193  $10 \mu\text{M H}_2\text{O}_2$  and increasing concentrations of Amplex Ultra Red (AR) (Invitrogen) ranging from  
15  
16  
17 194  $0.2$  to  $20 \mu\text{M}$ . The initial velocity of the enzymatic reaction was determined by monitoring the  
18  
19 195 formation of resorufin. The data was fitted using Graphpad Prism 7 software, obtaining  $K_M$ ,  $V_{max}$   
20  
21 and  $k_{cat}$  values.  
22  
23

24 197

25  
26 198 *UOX-HRP cascade kinetics*

27  
28 199 Both reactions were examined when in a cascade: UOX or UOX-loaded CNCs (final  
29  
30 concentration of  $3 \mu\text{g mL}^{-1}$ ) were added to HRP or HRP-loaded CNCs (final concentration  $300$   
31  
32  $\text{ng mL}^{-1}$ ) and both uric acid and AR were alternatively varied according to the previously listed  
33  
34 201 concentrations.  
35  
36 202  
37

38 203

39  
40 204 *Amplex Ultra Red conversion assay in a cascade*

41  
42 205 The same cascade reaction was tested at different conditions: UOX or UOX-loaded CNCs (final  
43  
44 206 concentration of  $3 \mu\text{g mL}^{-1}$ ) were added to HRP or HRP-loaded CNCs (final concentration  $300$   
45  
46  $\text{ng mL}^{-1}$ ), uric acid to a final concentration of  $10 \mu\text{M}$  and AR to a final concentration of  $1 \mu\text{M}$ ,  
47  
48 207 unless in controls where either substrate was missing and was substituted by the same volume of  
49  
50 208 PBS. The reaction profile in presence of catalase ( $1000 \text{ U mg}^{-1}$ , final concentration of  $10 \mu\text{g mL}^{-1}$   
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 210 <sup>1</sup>) was blanked against the reaction profile of catalase alone in presence of AR, as catalase too  
4  
5 211 has a heme center capable of reacting with the fluorogenic molecule.  
6  
7  
8 212

9  
10 213 *Catalytic nanocompartment resilience to degrading agents*  
11

12 214 Concentrations were 3  $\mu\text{g mL}^{-1}$  for UOX or UOX-CNC and 300  $\text{ng mL}^{-1}$  for HRP or HRP-CNC.  
13  
14 215 For the heat resistance assay, aliquots of the polymersome were incubated at 37, 50, 60 and 75  
15  
16 216  $^{\circ}\text{C}$  for either 10 or 30 minutes. For the chemical and enzymatic resistance assays, aliquots were  
17  
18 217 incubated with 6 M guanidine hydrochloride (GdnHCl) for 1 hour and 0.1  $\text{mg mL}^{-1}$  Proteinase K  
19  
20 218 for 2 hours (37  $^{\circ}\text{C}$ ), respectively. Proteinase K was added in excess with respect to the other  
21  
22 219 enzymes (free and encapsulated). The production of resorufin was compared to that of the  
23  
24 220 cascade reaction with no additional elements and the ratio was calculated. To verify unspecific  
25  
26 221 binding, the same amount of enzyme (either UOX or HRP) was added to pre-formed empty  
27  
28 222 vesicles and then purified with the same protocol, then mixed with vesicles encapsulating the  
29  
30 223 other enzyme and the cascade kinetics were followed.  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 224  
41 225 *Activity of CNCs in serum*  
42

43 226 Activity in biological fluid was tested in human blood serum in which uric acid was dissolved to  
44  
45 227 a final concentration of 500  $\mu\text{M}$  at 37  $^{\circ}\text{C}$ , mimicking hyperuricemia. UOX or UOX-CNCs were  
46  
47 228 added to reach a final concentration of 18  $\mu\text{g mL}^{-1}$ , HRP or HRP-CNCs to 900  $\text{ng mL}^{-1}$ , AR to 10  
48  
49 229  $\mu\text{M}$ . The decrease of absorbance at 290 nm was monitored over the course of 6 hours. The  
50  
51 230 degradation of uric acid was defined as  
52

52 231 
$$\text{Relative urate degradation} = \frac{\frac{\Delta\text{Abs}_{290}^{\text{with enzyme}}}{\text{min}}}{\frac{\Delta\text{Abs}_{290}^{\text{no enzyme}}}{\text{min}}}$$
  
53  
54  
55  
56 232

1  
2  
3 233 *Dependence of distance over reaction efficiency*

4  
5 234 Knowing the amount of CNCs in a given volume (obtained from FCS measurements), it was  
6  
7  
8 235 possible to calculate the mean inter-vesicle distance, assuming a cubic space occupied by the  
9  
10 236 compartments, as

$$\frac{1}{\sqrt[3]{N} \sqrt{V}}$$

11  
12  
13  
14  
15  
16  
17 237 where N is the number of particles (sum of UOX and HRP loaded-polymersomes) and V is the  
18  
19 238 reaction volume. A constant concentration of UOX-CNCs was mixed with a solution of HRP-  
20  
21  
22 239 CNCs at concentrations: 2x, 1x, 0.5x, 0.25x, 0.1x, 0.02x, 0.01x and 0.005x. The decrease in  
23  
24 240 concentration of HRP-CNCs induced an increase of the mean distance between polymersomes,  
25  
26 241 which was calculated using  $N = N_{\text{UOX-CNC}} + N_{\text{HRP-CNC}}$ . Resorufin production was monitored as  
27  
28  
29 242 described above.

30  
31 243

32  
33 244 *Cell culture*

34  
35 245 HEK293T cells were cultured in a humidified atmosphere with 5% CO<sub>2</sub> at 37 °C in Dulbecco's  
36  
37  
38 246 Modified Eagle Medium with GlutaMAX™-I (4.5 g L<sup>-1</sup> D-Glucose, Gibco life technologies) and  
39  
40 247 supplemented with 10% Fetal calf serum (FCS, BioConcept), 100 U mL<sup>-1</sup> penicillin and 100 µg  
41  
42 248 mL<sup>-1</sup> streptomycin (Sigma Aldrich).

43  
44  
45 249

46  
47 250 *Cell viability assay-MTS*

48  
49 251 For cell viability assessment, a CellTiter 96® Aqueous One Solution Cell Proliferation Assay  
50  
51  
52 252 (MTS, Promega) was used according to manufacturer instructions. Cells were seeded (5 000  
53  
54 253 cells/well in 100 µL cell culture medium) in a 96-well plate and incubated for 24 h. After 24 h

1  
2  
3 254 the UOX-HRP-CNCs (concentrations ranging from 1.18 to 18  $\mu\text{g mL}^{-1}$  of total polymer) were  
4  
5 255 diluted in PBS and added to the cells to reach a final volume of 200  $\mu\text{L}$ /well. After 24 h incubation  
6  
7 256 in presence of the CNCs, 20  $\mu\text{L}$  MTS reagent was added to each well. After 4 h absorbance was  
8  
9  
10 257 measured at 490 nm using a Spectramax M5e plate reader. Background absorbance from control  
11  
12 258 wells containing all assay components without cells was subtracted from each well and data  
13  
14 259 normalized to control cells containing all components except CNCs.  
15  
16  
17 260

### 19 261 *Cell viability in presence of uric acid*

20  
21 262 Cells were seeded at a density of 5 000 cells/well in 100  $\mu\text{L}$  cell culture medium, in a 96-well  
22  
23 263 plate and incubated for 24 h. Next, cells were dosed with 250 or 500  $\mu\text{M}$  of uric acid, final  
24  
25 264 concentration, in the presence or absence of UOX-HRP-CNCs (18  $\mu\text{g mL}^{-1}$  for UOX and 0.9  $\mu\text{g}$   
26  
27 265  $\text{mL}^{-1}$  for HRP, final concentrations in 200  $\mu\text{L}$  final volume) or in the presence of free enzymes  
28  
29 266 (UOX and HRP) at the same concentration. AR (1  $\mu\text{M}$ , final concentration in 200  $\mu\text{L}$  final  
30  
31 267 volume) was added to each well as a co-substrate for the HRP-CNCs. After a 24 h incubation  
32  
33 268 period, 20  $\mu\text{L}$  MTS reagent was added to each well. The absorbance was measured at 490 nm  
34  
35 269 after 4 h. Background absorbance from control wells containing all assay components apart from  
36  
37 270 the cells was subtracted from each well and data normalized to control cells containing all  
38  
39 271 components except CNCs and uric acid.  
40  
41  
42  
43  
44  
45 272

### 47 273 *Statistics*

48  
49 274 Multiple t-tests were performed using Graphpad Prism 7 software, comparing datasets, without  
50  
51 275 assuming constant standard deviation (SD). Statistical significance ( $p < 0.05$ ) was corrected using  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 276 the Holm-Sidak method. Significance was marked as \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ ,  
4  
5 277 sample size was always  $n = 3$ .  
6  
7

8 278

## 9 10 279 **Results and Discussion**

### 11 12 280 *Formation of UOX-Catalytic nanocompartments and HRP-Catalytic nanocompartments*

13  
14  
15 281 We encapsulated UOX and HRP inside the supramolecular assemblies formed during the self-  
16  
17 282 assembly process of the copolymer by using film rehydration method due to its mild conditions,  
18  
19 283 which do not affect the biomolecules.<sup>7, 30</sup> The architecture of the supramolecular assemblies in  
20  
21 284 presence and absence of enzymes was established by a combination of LS and TEM. We used  
22  
23 285 SLS to obtain the radius of gyration  $R_g$ , and DLS for the hydrodynamic radius  $R_h$ . The ratio of  
24  
25 286 these values  $R_g/R_h$ , called  $\rho$ -factor, is indicative of the different architectures, e.g. 1 for hollow  
26  
27 287 spheres while 0.77 for solid spheres.<sup>31</sup> In the case of empty supramolecular assemblies,  $R_g$  and  
28  
29 288  $R_h$  values were  $70 \pm 33$  nm and  $84 \pm 25$  nm respectively, and the calculated  $\rho$ -factor of 0.96  
30  
31 289 indicates hollow sphere architecture, thus formation of polymersomes. In the presence of UOX  
32  
33 290 (UOX-CNC), we determined for the supramolecular assemblies an  $R_g$  of  $68 \pm 12$  nm and  $R_h$  of  
34  
35 291  $73 \pm 33$  nm ( $\rho = 0.95$ ), while in the presence of HRP (HRP-CNC) they had an  $R_g$  of  $74 \pm 35$  nm  
36  
37 292 and  $R_h$   $85 \pm 41$  nm ( $\rho = 0.87$ ) (Figure S1). In both cases, the enzymes did not affect the self-  
38  
39 293 assembly process and resulted in polymersome architecture, which agrees with the TEM  
40  
41 294 micrographs (Figure 1A and 1C, Figure S2 and S3).  
42  
43  
44  
45  
46  
47


48 295 In order to quantify the amount of encapsulated enzymes inside the nanocompartments, we used  
49  
50 296 a combination of brightness measurements in FCS and BCA. FCS measures the fluorescence  
51  
52 297 fluctuations due to the Brownian motion of fluorescent species in a fL-sized volume, yielding  
53  
54 298 molecular parameters such as diffusion time and the number of particles that can be used to  
55  
56  
57  
58  
59  
60

1  
2  
3 299 evaluate interactions/encapsulation of the fluorescent dyes with/in supramolecular assemblies.<sup>32</sup>  
4  
5 300 By labeling the vesicle membrane with BODIPY 630/650, and using a 2-component fit (fixing  
6  
7 301 the diffusion time of free dye as one of the components) we obtained their average diffusion time  
8  
9  
10 302 ( $\tau_D$  5000  $\mu\text{s}$  for both CNCs, as compared to  $\tau_D = 57 \mu\text{s}$  of the free dye) and overall number of  
11  
12 303 fluorescent vesicles in solution. The fraction of dye-polymerosomes was 99% for UOX-CNCs and  
13  
14 304 94% for HRP-CNCs ( $2.6 \times 10^{11}$  and  $3.9 \times 10^{11}$  polymerosomes  $\mu\text{L}^{-1}$ , respectively), while that of the  
15  
16 305 free dye 1% and 4% thus indicating that most of the dye partitioned into the polymerosome  
17  
18  
19 306 membrane (Figure 1B and 1D).

20  
21  
22 307 A total protein concentration of  $30 \mu\text{g mL}^{-1}$  for UOX and  $18.6 \mu\text{g mL}^{-1}$  for HRP, was obtained  
23  
24 308 by BCA assay (Figure S4). Dividing the protein concentration by the number of polymerosomes  
25  
26 309 obtained by brightness measurements, we determined an average of  $11 \pm 7$  enzymes in UOX-  
27  
28  
29 310 CNCs and  $6 \pm 2$  enzymes in HRP-CNCs. An encapsulation efficiency of  $36 \pm 12 \%$  for UOX and  
30  
31 311  $22 \pm 4\%$  for HRP inside CNCs was obtained, in agreement with the encapsulation efficiency  
32  
33 312 values obtained for other enzymes inside polymerosomes.<sup>7, 30</sup> A number of 11  
34  
35  
36 313 OmpF/polymerosome was inserted as we used similar conditions as previously reported.<sup>33</sup> We  
37  
38  
39 314 kept the amount of porin constant in order to distinguish the effect of all other molecular factors  
40  
41 315 on the cascade reaction.

42  
43  
44  
45 316  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






317  
318 **Figure 1.** Formation of UOX-CNCs and HRP-CNCs. **A:** TEM micrograph of UOX-CNCs (scale bar: 200 nm). **B:** normalized  
319 FCS autocorrelation curve of the dye labeled UOX-CNCs (dots: normalized raw data; solid line: fitted data, black line: free  
320 BODIPY 630/650). **C:** TEM micrograph of HRP-CNCs (scale bar: 200 nm). **D:** normalized FCS autocorrelation curve of the  
321 dye-labeled HRP-CNCs (dots: normalized raw data; solid line: fitted data, black line: free BODIPY).

### 322 323 Overall enzymatic efficiency of CNCs

324 Having determined the amounts of encapsulated enzymes, we used the same concentrations in  
325 bulk to evaluate the efficiency of the cascade reaction. The cascade reaction takes place when the  
326 enzymes are free or encapsulated in separate nanocompartments equipped with OmpF (Figure  
327 2A). The reaction cannot proceed when the membrane of the nanocompartments is not equipped  
328 with OmpF, to allow molecular passage through (Figure 2B), or when one of the enzymes or  
329 substrates is removed from the cascade (Figure 2C).




330

331 **Figure 2.** Cascade reaction with different setups. *A:* Enzyme kinetics when both enzymes are free (red), only HRP is free (light  
332 green), only UOX is free (dark green) and both UOX and HRP are encapsulated inside polymersomes (blue). *B:* Cascade with  
333 permeabilized CNCs (blue), unpermeabilized UOX-loaded polymersomes (olive), unpermeabilized HRP-loaded polymersomes  
334 (black). *C:* Cascade reaction with both CNCs and the corresponding substrates (blue), and in the absence of one of the reaction

1  
2  
3 335 compounds: HRP (orange), UOX (brown), AR (grey), and uric acid (purple). Error bars are given as mean  $\pm$  SD ( $n = 3$ ), in some  
4 336 cases bars are smaller than the corresponding dot.  
5  
6  
7 337  
8  
9

10 338 As expected, the cascade reaction between separate nanocompartments is significantly slower  
11 339 than that of the free enzymes. Going a step further, we were interested in establishing the effect  
12 340 of the molecular diffusion through OmpF of substrates and products, examining the probability  
13 341 that the product of the first reaction penetrates in a second CNC containing the HRP and  
14 342 studying the effect of the distance between different CNCs on each step of the reaction and on its  
15 343 overall efficiency. The conversion of AR to resorufin (AR conversion) was used as a comparison  
16 344 standard, because it represents the last step of the cascade reaction and therefore accounts for  
17 345 whether the whole cascade reaction takes place. First, we studied the influence of molecular  
18 346 diffusion through OmpF as a key factor, which might limit the *in situ* enzymatic reaction inside  
19 347 CNCs. Having one of the enzymes free in solution and the second one encapsulated in the CNCs,  
20 348 AR conversion decreased compared with that of free enzymes. When HRP was surrounding  
21 349 UOX-CNCs, a slight decrease in AR conversion to 92% was observed, while when UOX was  
22 350 free around the HRP-CNCs, a significant decrease in AR conversion to 13% was obtained  
23 351 (Figure 3). When both enzymes were encapsulated within the CNCs working in tandem, AR  
24 352 conversion decreased significantly to 3% after 15 minutes. As H<sub>2</sub>O<sub>2</sub> is known to rapidly diffuse  
25 353 through OmpF and it passes through the same barriers (membrane and inter-vesicle space)  
26 354 regardless of which enzyme is inside the CNCs, its effect is only minor and is due to its  
27 355 probability to interact with HRP. When only UOX is inside the CNCs, the slight decrease in AR  
28 356 conversion is due to an inhomogeneous distribution of UOX-CNCs, which are the only source of  
29 357 H<sub>2</sub>O<sub>2</sub>. When HRP is inside the CNCs, the greater decrease in AR conversion is related to the  
30 358 slow diffusion of AR through the OmpF pores, which is also the bottleneck for the cascade  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 359 reaction between CNCs in tandem. Another factor that contributes to the significant decrease in  
4  
5 360 the reaction efficiency when CNCs are in tandem is the inhomogeneous CNC distribution which  
6  
7 361 reduces the probability that the substrates of the second reaction reach the HRP-CNCs. Besides,  
8  
9 362 the necessity of  $H_2O_2$  transfer from UOX-CNCs to HRP-CNCs is proven by introducing free  
10  
11 363 catalase to the reaction mixture, as a competing enzyme that converts  $H_2O_2$  to water and oxygen  
12  
13 364 (without Amplex Red as co-factor): when added, catalase strongly hinders the reaction mediated  
14  
15 365 by HRP (Figure S5A).



367 **Figure 3.** Conversion of AR to resorufin by a cascade enzymatic reaction when: both enzymes are encapsulated (blue), and only  
368 HRP is encapsulated (HRP-CNCs) and UOX is free (yellow), only UOX is encapsulated (UOX-CNCs) and HRP is free (green),  
369 both enzymes are free (red). Error bars are given as mean  $\pm$  SD ( $n = 3$ ).

1  
2  
3 371 *Kinetic analysis of CNCs*  
4

5 372 It is already known that encapsulation in polymersomes affects the kinetic parameters of  
6  
7 373 enzymes, by increasing their affinity for the substrates or decreasing the velocity, because they  
8  
9  
10 374 are in a different environment than in solution.<sup>30</sup> To characterize the behavior of CNCs, we first  
11  
12 375 compared the kinetic parameters of CNCs when isolated and then when acting in tandem by  
13  
14 376 using the Michaelis-Menten model (Table 1 and 2, Figure S6). Both steps of the cascade reaction  
15  
16 377 can be modeled in a first approximation by using Michaelis-Menten kinetics because in the first  
17  
18 378 reaction (UOX-CNCs) uric acid is added in excess, and for the second step both substrates are in  
19  
20 379 excess in the surroundings of the HRP-CNCs (AR added in excess in the medium, and H<sub>2</sub>O<sub>2</sub>  
21  
22  
23 380 generated by UOX-CNCs with  $V_{\max}$  of  $1.47 \times 10^{-3}$   $\mu\text{M}/\text{min}$ , which is one order of magnitude  
24  
25 381 higher than  $V_{\max}$  of HRP, as presented in Table 1 and 2).

26  
27  
28  
29 382  $K_M$ , the Michaelis-Menten constant, defines the affinity of the enzyme for the substrate, and the  
30  
31 383 apparent  $V_{\max}$  represents the maximal velocity at which the enzyme operates once it is saturated  
32  
33 384 by the substrate. As both  $K_M$  and  $V_{\max}$  are intrinsic characteristics of the enzymes in specific  
34  
35 385 conditions, it is expected that these parameters are not affected by the enzyme encapsulation (if  
36  
37 386 the substrate/products diffusion is not changing due to possible barriers). However, we observe a  
38  
39 387 completely different situation: both  $K_M$  and  $V_{\max}$  are affected by enzyme encapsulation (Table 1  
40  
41 388 and 2).

42  
43  
44  
45 389 The apparent  $K_M$  of both enzymes is lowered once confined in the nanocompartment, 4-times for  
46  
47 390 UOX-CNC and 1.5 times for HRP-CNC, which is in agreement with a previous publication  
48  
49 391 where encapsulated enzymes tend to exhibit a lowering in  $K_M$ .<sup>34</sup> However, this is not surprising  
50  
51 392 as the hollow cavity of a polymersome offers a more confined space, increasing the probability  
52  
53  
54 393 of the substrate to access the catalytic center of the enzyme.<sup>30</sup> In addition, there is a decrease in  
55  
56  
57  
58  
59  
60

394  $V_{\max}$  and  $k_{\text{cat}}$  values. The decrease of both  $V_{\max}$  and  $k_{\text{cat}}$  is significant in the case when UOX is  
 395 encapsulated in the CNCs (both for free HRP and for HRP-CNCs) (Table 1). On the contrary,  
 396 when HRP is encapsulated (free UOX and UOX-CNCs), the decrease in  $V_{\max}$  and  $k_{\text{cat}}$  values is  
 397 noticeably smaller (Table 2). We assume the change in  $k_{\text{cat}}$  values is associated with a slower  
 398 influx of the substrates to the enzyme's active site, a slower efflux of the products or a  
 399 combination thereof when the enzymes are inside the CNCs due to various barriers associated  
 400 with the polymersomes architecture. Similarly,  $k_{\text{cat}}/K_M$  values decrease when the enzymes are  
 401 inside the CNCs. While the substrate can easily encounter the enzyme once inside the  
 402 compartment, the permeation through the membrane that is mediated by OmpF pores effectively  
 403 hinders the total activity of the cascade. The effect of diffusion to the enzyme is a well-known  
 404 parameter affecting and altering enzyme kinetics, as it can become the actual limiting factor in  
 405 their efficiency.<sup>35-36</sup>

**Table 1.** Apparent kinetic parameters for UOX: Michaelis-Menten constant ( $K_M$ ), maximal enzyme velocity ( $V_{\max}$ ), turnover rate ( $k_{\text{cat}}$ ) and catalytic efficiency ( $k_{\text{cat}}/K_M$ ).

	Free UOX	Free UOX in cascade	UOX-CNC	UOX-CNC in cascade
$K_M$ ( $\mu\text{M}$ )	$3.70 \times 10^2$	$3.68 \times 10^2$	$8.32 \times 10^1$	$9.09 \times 10^1$
$V_{\max}$ ( $\mu\text{M}/\text{min}$ )	$2.47 \times 10^{-1}$	$2.77 \times 10^{-1}$	$1.22 \times 10^{-4}$	$1.47 \times 10^{-3}$
$k_{\text{cat}}$ (1/s)	2.72	2.55	$1.34 \times 10^{-3}$	$2.00 \times 10^{-3}$
$k_{\text{cat}}/K_M$ (1/( $\mu\text{M s}$ ))	$7.30 \times 10^{-3}$	$7.52 \times 10^{-3}$	$1.60 \times 10^{-5}$	$2.20 \times 10^{-5}$

406

**Table 2.** Apparent kinetic parameters for UOX: Michaelis-Menten constant ( $K_M$ ), maximal enzyme velocity ( $V_{max}$ ), turnover rate ( $k_{cat}$ ) and catalytic efficiency ( $k_{cat}/K_M$ ).

	<b>Free HRP</b>	<b>Free HRP in cascade</b>	<b>HRP-CNC</b>	<b>HRP-CNC in cascade</b>
$K_M$ ( $\mu\text{M}$ )	$3.50 \times 10$	$3.0 \times 10$	$2.22 \times 10$	$1.92 \times 10$
$V_{max}$ ( $\mu\text{M}/\text{min}$ )	$7.82 \times 10^{-4}$	$8.19 \times 10^{-4}$	$4.21 \times 10^{-5}$	$1.32 \times 10^{-4}$
$k_{cat}$ (1/s)	$1.14 \times 10^{-2}$	$1.12 \times 10^{-2}$	$1.94 \times 10^{-3}$	$6.19 \times 10^{-3}$
$k_{cat}/K_M$ (1/M/s)	$4.10 \times 10^{-4}$	$4 \times 10^{-4}$	$2.80 \times 10^{-4}$	$3.22 \times 10^{-4}$

407

408 We exclude that the decrease in enzyme activity inside the CNCs is due to the confinement of  
 409 enzymes: encapsulated UOX (molecular radius  $4.27 \text{ nm}^{37}$ ) and HRP (molecular radius  $2.98$   
 410  $\text{nm}^{38}$ ) move free in a 1000-fold and 12000-fold greater volume inside the polymersome than their  
 411 intrinsic volume, respectively. We calculated the inner volume of polymersomes as the volume  
 412 of a sphere with a radius  $R = R_h - d$ , where  $d$  is the polymersome membrane thickness of  $10.7$   
 413  $\text{nm}$  (previously determined for  $\text{PMOXA}_6\text{-PDMS}_{44}\text{-PMOXA}_6$  compartments<sup>39</sup>).

#### 414 *Role of compartmentalization on CNC activity*

415 In a similar manner as is the case for liposomes, the polymeric membrane of nanocompartments  
 416 is expected to offer protection of the encapsulated payload from external agents that would  
 417 degrade it, as for example proteolytic attack.<sup>40</sup> We wanted to establish the protective role of the

1  
2  
3 418 nanocompartments in the presence of physical factors such as high temperatures and different pH  
4  
5 419 values as well as degrading agents (GdnHCl and Proteinase K). We quantified the “activity  
6  
7 420 retention” as the ratio between the production of resorufin under standard conditions (RT, pH 7)  
8  
9 421 and in the presence of degrading conditions. Wild-type OmpF is known to be stable at relatively  
10  
11 422 extreme pH,<sup>41-43</sup> resistant to proteolysis,<sup>44</sup> chaotropic agents and temperatures up to 75 °C.<sup>43</sup>  
12  
13  
14 423 Therefore, the porin is neither affected by the mild conditions of the rehydration method used to  
15  
16 424 generate the catalytic compartments, nor by the presence of a more complex environment or  
17  
18 425 degrading agents, because it is also protected inside the compartments membrane.  
19  
20  
21 426 While below 37°C both encapsulated and free enzymes preserve their activity, for higher  
22  
23 427 temperatures, a decrease in activity is observed, but to a significantly higher degree for the free  
24  
25 428 enzymes (Figure 4A, Figure S5D and S7). The ability of the polymeric membrane to protect the  
26  
27 429 encapsulated payload from the effect of higher temperatures,<sup>45-46</sup> which denatures the enzymes,  
28  
29 430 is essential for translational applications. The effect of pH was less straight forward, as these two  
30  
31 431 enzymes have a different pH optima: basic for UOX and acidic for HRP.<sup>47-48</sup> While at pH 3 there  
32  
33 432 is no apparent gain in activity from the enzyme encapsulation, at pH 9 the CNCs are significantly  
34  
35 433 more active than the free enzymes acting in tandem (Figure 4B). The enzyme activity is further  
36  
37 434 affected upon encapsulation due to a complex scenario: i) the interplay between the lower  
38  
39 435 stability of HRP at higher pH values<sup>49</sup> and the basic pH optimum of UOX, ii) the stabilization of  
40  
41 436 HRP –known to interact with hydrophobic substrates<sup>50</sup> – once inside the compartment, and iii) an  
42  
43 437 increase in enzyme accessibility for the substrates due to the confined reaction space.<sup>30</sup> Therefore  
44  
45 438 the effect of the pH on activity is less evident when the enzymes are free in solution and no  
46  
47 439 confinement effects are present. However, we chose a neutral pH to evaluate the CNCs in  
48  
49 440 tandem to be closer to physiological conditions, at which both enzymes are still active (Figure  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




1  
2  
3 441 S5B), and where both the free enzymes and encapsulated ones have similar activity retention  
4  
5 442 values.

6  
7 443 The addition of an enzyme denaturing chemical agent, such as GdnHCl, decreased the enzyme  
8  
9 444 activity, which is significantly more pronounced when the enzymes are free. This clearly  
10  
11 445 indicates the protective role of compartmentalization (Figure 4C). The decrease in activity  
12  
13 446 retention values in the case of CNCs in tandem is mainly due to the diffusion of GdnHCl (95 Da)  
14  
15 447 through OmpF, which has a weight cut-off of 650 Da.<sup>51</sup> Even though in a previous report  
16  
17 448 GdnHCl diffused through the polymersome membrane,<sup>52</sup> this is not observed here as shown by  
18  
19 449 the highly retained activity. The permeability of PMOXA-PDMS-PMOXA membranes varies  
20  
21 450 depending on the molecular factors, such as the thickness of the membrane, the polydispersity of  
22  
23 451 the copolymer chains or the conditions in which they are formed. In addition to the small number  
24  
25 452 of inserted OmpF that are enough to allow *in situ* enzymatic reaction, the innate resistance  
26  
27 453 towards denaturation of UOX<sup>53-54</sup> and the possible stabilization of HRP due to interactions with  
28  
29 454 the membrane are responsible for maintaining enzymes' activity in the case of our CNCs, even in  
30  
31 455 presence of GdnHCl.

32  
33 456 To mimic a proteolytic attack, we added Proteinase K both to free enzymes and the CNCs for 2  
34  
35 457 hours. While a significant decrease in activity retention was observed for the free enzymes ( $18 \pm$   
36  
37 458 1%), in the case of CNCs the decrease was considerably smaller ( $83 \pm 3\%$ ), additionally showing  
38  
39 459 that a small fraction of enzyme molecules was adsorbed at the outer interface of the  
40  
41 460 polymersome<sup>33</sup> (Figure 4D). We considered the overall activity of the CNCs as a whole;  
42  
43 461 however, by adding free enzymes to empty vesicles and then purifying them, it was possible to  
44  
45 462 detect a certain amount of activity due to unspecific binding in the cascade for HRP, estimated to  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

463 be around 3% of the total (Figure S5C and Table S1). The auto-oxidation of AR was also taken  
 464 into account, and subtracted in all blanks.



465  
 466 **Figure 4.** Stability of catalytic nanocompartments and free enzymes (activity normalized against CNCs (blue) or enzymes (red) at  
 467 RT, neutral pH, no agents). **A:** protection from heat. **B:** protection from extreme pH. **C:** protection from denaturing agent  
 468 GdnHCl. **D:** protection from proteolysis. Error bars are given as mean  $\pm$  SD (multiple *t*-test, \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p <$   
 469  $0.001$ ,  $n = 3$ ).


470

#### 471 The effect of distance on the efficiency of the CNCs in tandem

472 The passage through barriers and diffusion between compartments represents an essential point  
 473 in bio-communication because products have, in some cases, to travel to different cellular  
 474 compartments or take part in inter-cellular communication. Most organelle-to-organelle

1  
2  
3 475 communications in the cell happen via close association below 50 nm<sup>55</sup> and the average synaptic  
4  
5 476 cleft is around 20 nm,<sup>56</sup> whereas it is estimated that a single cell can effectively communicate  
6  
7 477 between 5 and 10  $\mu\text{m}$  in autocrine signaling and up to 250  $\mu\text{m}$  in paracrine signaling.<sup>57-58</sup> In such  
8  
9 478 cases of communication between organelles or cells, there is no longer a homogeneous  
10  
11 479 distribution of enzymes or receptors but local high concentrations and otherwise empty or low  
12  
13 480 density interstices. We used our CNCs in tandem to mimic communication between bio-  
14  
15 481 assemblies and see the effect of distance on the overall cascade reaction efficiency. We assumed  
16  
17 482 a cubic volume for the compartments, so that the mean inter-compartment distance is calculated,  
18  
19 483 based on the polymersome density obtained by FCS.

20  
21  
22  
23  
24 484 The AR conversion values in the case of CNCs in tandem remains almost constant (with some  
25  
26 485 values higher than 100% as values fluctuate around the mean obtained at 0.8  $\mu\text{m}$ , set as  
27  
28 486 reference) until the mean distance between CNCs is 1.3  $\mu\text{m}$ , then the values decrease  
29  
30 487 significantly. This suggests that the diffusion of molecules through the OmpF pores represents  
31  
32 488 the dominant factor for distances lower than approximately 1.30  $\mu\text{m}$ . Interestingly, the ratio  
33  
34 489 between the mean inter-compartment distance and their diameter is about 10, which has the same  
35  
36 490 order of magnitude as the ratio between a mean cell-cell communication distance for cells with a  
37  
38 491 1  $\mu\text{m}$  diameter, such as bacteria.<sup>59</sup> For distances between CNCs higher than 1.3  $\mu\text{m}$ , the cascade  
39  
40 492 reaction is rapidly hindered due to a decrease in the probability that  $\text{H}_2\text{O}_2$  encounters a HRP-  
41  
42 493 CNC (Figure 5). These distances are consistent with distances typical for autocrine signaling.  
43  
44 494 Therefore our findings, based on tandem CNCs in a simplified medium, represents a first  
45  
46 495 necessary step for better understanding cell communication.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



496

497 **Figure 5.** AR conversion by cascade reaction inside CNCs in tandem at different mean inter-vesicle distances. Error bars are  
 498 given as mean  $\pm$  SD ( $n = 3$ ).

499 *CNCs in tandem in biologic conditions*


500 We then evaluated the functionality of the CNCs in biological conditions, both in biofluids and  
 501 upon incubation with cells, as more appropriate to advance translational applications. First, we  
 502 used human blood serum where uric acid was dissolved to reach levels similar to those  
 503 considered typical for hyperurcemia ( $>6.8$  mg dL<sup>-1</sup> in men<sup>60</sup>). A simple model, defined as

504 
$$\frac{\frac{\Delta Abs_{290}^{with\ enzyme}}{min}}{\frac{\Delta Abs_{290}^{no\ enzyme}}{min}}$$
 for the dilutions of HRP-CNCs, gives the relative efficiency of the cascade

505 reaction, which we called Relative Urate Degradation (R.U.D.) (Figure 6A). Interestingly, in  
 506 such a complex medium, CNCs facilitate the clearance of uric acid at a comparable rate to the  
 507 free enzyme. The addition of HRP removes H<sub>2</sub>O<sub>2</sub>, pulling the first reaction forward according to  
 508 Le Chatelier's principle. In addition, we observed no aggregation of polymersomes in serum, in  
 509 agreement with reported results on similar polymers.<sup>61</sup> Note that only in PBS the free enzymes

1  
2  
3 510 are better in terms of the cascade efficiency than when encapsulated inside polymersomes.  
4  
5 511 However, in serum, they perform similarly, which emphasizes the role of the compartments in  
6  
7 512 protecting the encapsulated enzymes in these conditions (37 °C, 6 hours), and support our  
8  
9 513 approach for further cell assessment. Further studies, beyond the scope of the present one, are  
10  
11 514 necessary to understand the bio-molecular factors affecting the efficiency of the overall cascade  
12  
13 515 reaction between CNCs in human serum.  
14  
15

16  
17 516 Second, we determined the ability of the CNCs to metabolize uric acid and degrade H<sub>2</sub>O<sub>2</sub> upon  
18  
19 517 incubation with cells, as an essential step towards medical applications. First, we evaluated the  
20  
21 518 cytotoxicity of CNCs when incubated with HEK293T cells overnight at different concentrations  
22  
23 519 of the CNCs (measured in polymer concentration) by MTS assay. CNCs have no cytotoxic effect  
24  
25 520 towards the cells, even at the highest polymer concentration (0.19 μg mL<sup>-1</sup>) (Figure 6B). Next,  
26  
27 521 CNCs were incubated with HEK293T epithelial cells for 24 h in the presence of increasing  
28  
29 522 amounts of uric acid (250 and 350 μM): at physiological concentration and at the lower end of  
30  
31 523 hyperuricemia values. CNCs, known to be eventually internalized by cells,<sup>7</sup> were added together  
32  
33 524 with uric acid because it accumulates extracellularly to toxic levels: in this manner CNCs  
34  
35 525 directly protect cells by degrading uric acid. Cell viability decreased to around 60% in the  
36  
37 526 presence of 250 μM uric acid. By addition of either free enzymes or the CNCs, the cell viability  
38  
39 527 was unaffected by the presence of uric acid. Increasing the amount of uric acid to 350 μM  
40  
41 528 reduces the viability of the cells to 2%, while the cascade reaction of the free enzymes and of the  
42  
43 529 CNCs in tandem induce a protective effect against uric acid. In addition, due to the combination  
44  
45 530 of enzymes, H<sub>2</sub>O<sub>2</sub> is also degraded as a result of the successful cascade reaction process (Figure  
46  
47 531 6C and D).  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



532  
533 **Figure 6.** Activity of CNCs and free enzymes in blood serum and their interaction with cells. **A:** clearance of urate with both  
534 CNCs (solid blue), UOX-CNC only (striped blue, no HRP-CNC), both free enzymes (solid red) and UOX only (striped red, no  
535 HRP-CNC) **B:** cell viability of HEK293T cells incubated with CNCs at different concentrations (expressed as polymer  
536 concentration). **C:** scheme of the CNC-cell interaction and detoxifying activity of the UOX-HRP cascade on cells only (green),  
537 cells with free enzymes (blue) and cells with CNCs (red). Error bars are given as mean  $\pm$  SD (multiple *t*-test, \*  $p < 0.05$ , \*\*  $p <$   
538  $0.01$ , \*\*\*  $p < 0.001$ ,  $n = 3$ ).

## 539 Conclusions

540 We designed two spatially segregated catalytic nanocompartments to support a cascade reaction  
541 between them, mimicking sequential reactions between biosystems. By an elegant selection of

1  
2  
3 542 the enzyme combination, we applied these catalytic nanocompartments in tandem to decrease  
4  
5 543 uric acid and H<sub>2</sub>O<sub>2</sub>, both involved in various pathologic conditions ranging from gout to  
6  
7 544 oxidative stress. A thorough analysis of the factors affecting the overall efficiency of the cascade  
8  
9 545 reaction between CNCs indicated the protective role of the compartments, which provide a shield  
10  
11 546 for the encapsulated enzymes, especially important in biological fluids and cellular environment.  
12  
13 547 For the first time, a kinetic evaluation of a cascade reaction between segregated reaction spaces  
14  
15 548 at the nanoscale has been achieved. We elucidated the limiting factors for the overall reaction: i)  
16  
17 549 the diffusion through the membrane pores inserted into the walls of the compartments and ii) the  
18  
19 550 probability of the products from the first reaction to encounter CNCs containing the second  
20  
21 551 enzyme and reach the encapsulated enzyme molecules. A balance is necessary between the  
22  
23 552 protective role of the nanocompartments and the factors that decrease the efficiency of the  
24  
25 553 cascade reaction for translational applications. This cascade reaction in separate compartments  
26  
27 554 has been successfully performed in serum and then used to decrease both uric acid and the  
28  
29 555 derived H<sub>2</sub>O<sub>2</sub> from the cellular milieu as a first step towards medical applications. Our study is  
30  
31 556 the first one that proves that a two-compartment cascade reaction acts in cellular conditions, thus  
32  
33 557 contributing to the understanding of the design of complex catalytic compartments to cope with  
34  
35 558 biological requirements.  
36  
37  
38  
39  
40  
41  
42  
43  
44

## 45 560 **Supporting Information**

46  
47 561 Supporting information: additional physical characterization, enzymatic assays in various  
48  
49 562 conditions, Michaelis-Menten curves. (PDF)  
50  
51

## 52 563 **Corresponding Author**

53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 564 Prof. Dr. Cornelia G. Palivan, Department of Chemistry, Physical Chemistry, Mattenstrasse 24a,  
4  
5 565 CH-4058 Basel  
6  
7 566 cornelia.Palivan@unibas.ch  
8  
9

## 10 567 **Author Contributions**

11  
12  
13 568 A.B contributed to the CNCs production and characterization, I.C contributed to the *in vitro*  
14  
15 569 assays, J.L. contributed to experiment design and enzymatic assays, and C.G.P contributed to the  
16  
17 570 concept of CNCs in tandem. The manuscript was written through contributions of all authors.  
18  
19  
20 571 All authors have given approval to the final version of the manuscript.  
21  
22

## 23 572 **Acknowledgements**

24  
25 573 We gratefully acknowledge the financial support provided by the Swiss National Science  
26  
27 574 Foundation, the University of Basel and the National Centre of Competence in Research –  
28  
29 575 Molecular Systems Engineering. Authors thank Prof. Wolfgang Meier (University of Basel) for  
30  
31 576 providing the polymer, Dr. Samuel Lörcher for its synthesis and Gabriele Persy for the TEM  
32  
33 577 measurements. A.B. thanks Dr. Tomaž Einfalt (University of Basel) for the fruitful help and  
34  
35 578 discussions on handling of OmpF, and Prof. Lucio Isa (ETHZ), for his suggestion regarding the  
36  
37 579 distance mode. Authors thank Federica Rasa for the help with the illustrations.  
38  
39  
40  
41  
42 580  
43  
44

## 45 581 **REFERENCES**

- 46  
47  
48 582 1. Kuchler, A.; Yoshimoto, M.; Luginbuhl, S.; Mavelli, F.; Walde, P., Enzymatic reactions  
49 583 in confined environments. *Nat Nanotechnol* **2016**, *11* (5), 409-20.  
50  
51 584 2. Agapakis, C. M.; Boyle, P. M.; Silver, P. A., Natural strategies for the spatial  
52 585 optimization of metabolism in synthetic biology. *Nat Chem Biol* **2012**, *8* (6), 527-35.  
53 586 3. Hosta-Rigau, L.; York-Duran, M. J.; Zhang, Y.; Goldie, K. N.; Stadler, B., Confined  
54 587 multiple enzymatic (cascade) reactions within poly(dopamine)-based capsosomes. *ACS Appl*  
55 588 *Mater Interfaces* **2014**, *6* (15), 12771-9.  
56  
57  
58  
59  
60



- 1  
2  
3 589 4. Sakr, O. S.; Borchard, G., Encapsulation of Enzymes in Layer-by-Layer (LbL)  
4 590 Structures: Latest Advances and Applications. *Biomacromolecules* **2013**, *14* (7), 2117-2135.
- 5 591 5. Palivan, C. G.; Fischer-Onaca, O.; Delcea, M.; Itel, F.; Meier, W., Protein-polymer  
6 592 nanoreactors for medical applications. *Chem Soc Rev* **2012**, *41* (7), 2800-23.
- 7 593 6. Schoonen, L.; van Hest, J. C., Compartmentalization Approaches in Soft Matter Science:  
8 594 From Nanoreactor Development to Organelle Mimics. *Adv Mater* **2016**, *28* (6), 1109-28.
- 9 595 7. Tanner, P.; Onaca, O.; Balasubramanian, V.; Meier, W.; Palivan, C. G., Enzymatic  
10 596 cascade reactions inside polymeric nanocontainers: a means to combat oxidative stress.  
11 597 *Chemistry* **2011**, *17* (16), 4552-60.
- 12 598 8. Blackman, L. D.; Varlas, S.; Arno, M. C.; Fayter, A.; Gibson, M. I.; O'Reilly, R. K.,  
13 599 Permeable Protein-Loaded Polymersome Cascade Nanoreactors by Polymerization-Induced Self-  
14 600 Assembly. *ACS Macro Lett* **2017**, *6* (11), 1263-1267.
- 15 601 9. Peters, R. J.; Marguet, M.; Marais, S.; Fraaije, M. W.; van Hest, J. C.; Lecommandoux,  
16 602 S., Cascade reactions in multicompartmentalized polymersomes. *Angew Chem Int Ed Engl* **2014**,  
17 603 *53* (1), 146-50.
- 18 604 10. Grafe, D.; Gaitzsch, J.; Appelhans, D.; Voit, B., Cross-linked polymersomes as  
19 605 nanoreactors for controlled and stabilized single and cascade enzymatic reactions. *Nanoscale*  
20 606 **2014**, *6* (18), 10752-61.
- 21 607 11. Taek, K. K.; M., C. J. J. L.; M., N. R. J.; M., v. H. J. C., A Polymersome Nanoreactor  
22 608 with Controllable Permeability Induced by Stimuli-Responsive Block Copolymers. *Advanced*  
23 609 *Materials* **2009**, *21* (27), 2787-2791.
- 24 610 12. Schmitt, C.; Lippert, A. H.; Bonakdar, N.; Sandoghdar, V.; Voll, L. M.,  
25 611 Compartmentalization and Transport in Synthetic Vesicles. *Front Bioeng Biotechnol* **2016**, *4*, 19.
- 26 612 13. Lomora, M.; Garni, M.; Itel, F.; Tanner, P.; Spulber, M.; Palivan, C. G., Polymersomes  
27 613 with engineered ion selective permeability as stimuli-responsive nanocompartments with  
28 614 preserved architecture. *Biomaterials* **2015**, *53* (0), 406-414.
- 29 615 14. van Oers, M. C.; Rutjes, F. P.; van Hest, J. C., Cascade reactions in nanoreactors. *Curr*  
30 616 *Opin Biotechnol* **2014**, *28*, 10-6.
- 31 617 15. Bolinger, P. Y.; Stamou, D.; Vogel, H., An integrated self-assembled nanofluidic system  
32 618 for controlled biological chemistries. *Angew Chem Int Ed Engl* **2008**, *47* (30), 5544-9.
- 33 619 16. Brasch, M.; Putri, R. M.; de Ruyter, M. V.; Luque, D.; Koay, M. S.; Caston, J. R.;  
34 620 Cornelissen, J. J., Assembling Enzymatic Cascade Pathways inside Virus-Based Nanocages  
35 621 Using Dual-Tasking Nucleic Acid Tags. *J Am Chem Soc* **2017**, *139* (4), 1512-1519.
- 36 622 17. Marguet, M.; Bonduelle, C.; Lecommandoux, S., Multicompartmentalized polymeric  
37 623 systems: towards biomimetic cellular structure and function. *Chem Soc Rev* **2013**, *42* (2), 512-29.
- 38 624 18. Godoy-Gallardo, M.; Labay, C.; Jansman, M. M. T.; Ek, P. K.; Hosta-Rigau, L.,  
39 625 Intracellular Microreactors as Artificial Organelles to Conduct Multiple Enzymatic Reactions  
40 626 Simultaneously. *Advanced Healthcare Materials* **2016**, *6* (4), 1601190.
- 41 627 19. Kuiper, S. M.; Nallani, M.; Vriezema, D. M.; Cornelissen, J. J.; van Hest, J. C.; Nolte, R.  
42 628 J.; Rowan, A. E., Enzymes containing porous polymersomes as nano reaction vessels for cascade  
43 629 reactions. *Org Biomol Chem* **2008**, *6* (23), 4315-8.
- 44 630 20. Liu, X.; Formanek, P.; Voit, B.; Appelhans, D., Functional Cellular Mimics for the  
45 631 Spatiotemporal Control of Multiple Enzymatic Cascade Reactions. *Angewandte Chemie*  
46 632 *International Edition* **2017**, *56* (51), 16233-16238.

- 1  
2  
3 633 21. Wang, Z.; van Oers, M. C. M.; Rutjes, F. P. J. T.; van Hest, J. C. M., Polymersome  
4 634 Colloidosomes for Enzyme Catalysis in a Biphasic System. *Angewandte Chemie* **2012**, *124* (43),  
5 635 10904-10908.
- 6 636 22. Wertheimer, A.; Morlock, R.; Becker, M. A., A revised estimate of the burden of illness  
7 637 of gout. *Current therapeutic research, clinical and experimental* **2013**, *75*, 1-4.
- 8 638 23. Lörcher, S.; Meier, W., Cosolvent fractionation of PMOXA-b-PDMS-b-PMOXA: Bulk  
9 639 separation of triblocks from multiblocks. *European Polymer Journal* **2017**, *88*, 575-585.
- 10 640 24. Nardin, C.; Thoeni, S.; Widmer, J.; Winterhalter, M.; Meier, W., Nanoreactors based on  
11 641 (polymerized) ABA-triblock copolymer vesicles. *Chemical Communications* **2000**, (15), 1433-  
12 642 1434.
- 13 643 25. Azmi, N. E.; Ramli, N. I.; Abdullah, J.; Abdul Hamid, M. A.; Sidek, H.; Abd Rahman,  
14 644 S.; Ariffin, N.; Yusof, N. A., A simple and sensitive fluorescence based biosensor for the  
15 645 determination of uric acid using H<sub>2</sub>O<sub>2</sub>-sensitive quantum dots/dual enzymes. *Biosens*  
16 646 *Bioelectron* **2015**, *67*, 129-33.
- 17 647 26. Dai, M.; Huang, T.; Chao, L.; Xie, Q.; Tan, Y.; Chen, C.; Meng, W., Horseradish  
18 648 peroxidase-catalyzed polymerization of L-DOPA for mono-/bi-enzyme immobilization and  
19 649 amperometric biosensing of H<sub>2</sub>O<sub>2</sub> and uric acid. *Talanta* **2016**, *149*, 117-123.
- 20 650 27. Miland, E.; Miranda Ordieres, A. J.; Tunon Blanco, P.; Smyth, M. R.; Fagain, C. O.,  
21 651 Poly(o-aminophenol)-modified bienzyme carbon paste electrode for the detection of uric acid.  
22 652 *Talanta* **1996**, *43* (5), 785-96.
- 23 653 28. Einfalt, T.; Goers, R.; Dinu, I. A.; Najer, A.; Spulber, M.; Onaca-Fischer, O.; Palivan, C.  
24 654 G., Stimuli-Triggered Activity of Nanoreactors by Biomimetic Engineering Polymer  
25 655 Membranes. *Nano Lett* **2015**, *15* (11), 7596-603.
- 26 656 29. JW. Krieger; Langowski, J. *QuickFit 3.0: A data evaluation application for biophysics*,  
27 657 <http://www.dkfz.de/Macromol/quickfit/>, 2015.
- 28 658 30. Baumann, P.; Spulber, M.; Fischer, O.; Car, A.; Meier, W., Investigation of Horseradish  
29 659 Peroxidase Kinetics in an "Organelle-Like" Environment. *Small* **2017**, *13* (17).
- 30 660 31. Stauch, O.; Schubert, R., Structure of Artificial Cytoskeleton Containing Liposomes in  
31 661 Aqueous Solution Studied by Static and Dynamic Light Scattering. *Biomacromolecules* **2002**.
- 32 662 32. Habel, J.; Ogbonna, A.; Larsen, N.; Cherre, S.; Kynde, S.; Midtgaard, S. R.; Kinoshita,  
33 663 K.; Krabbe, S.; Jensen, G. V.; Hansen, J. S.; Almdal, K.; Helix-Nielsen, C., Selecting analytical  
34 664 tools for characterization of polymersomes in aqueous solution. *RSC Advances* **2015**, *5* (97),  
35 665 79924-79946.
- 36 666 33. Edlinger, C.; Einfalt, T.; Spulber, M.; Car, A.; Meier, W.; Palivan, C. G., Biomimetic  
37 667 Strategy To Reversibly Trigger Functionality of Catalytic Nanocompartments by the Insertion of  
38 668 pH-Responsive Biovalves. *Nano Lett* **2017**, *17* (9), 5790-5798.
- 39 669 34. Chen, Q.; Schönherr, H.; Vancso, G. J., Block-Copolymer Vesicles as Nanoreactors for  
40 670 Enzymatic Reactions. *Small* **2009**, *5* (12), 1436-1445.
- 41 671 35. Bar-Even, A.; Noor, E.; Savir, Y.; Liebermeister, W.; Davidi, D.; Tawfik, D. S.; Milo, R.,  
42 672 The moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme  
43 673 parameters. *Biochemistry* **2011**, *50* (21), 4402-10.
- 44 674 36. Garcia-Viloca, M.; Gao, J.; Karplus, M.; Truhlar, D. G., How enzymes work: analysis by  
45 675 modern rate theory and computer simulations. *Science* **2004**, *303* (5655), 186-95.
- 46 676 37. Caliceti, P.; Schiavon, O.; Veronese, F. M., Biopharmaceutical properties of uricase  
47 677 conjugated to neutral and amphiphilic polymers. *Bioconjug Chem* **1999**, *10* (4), 638-46.
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 678 38. Rennke, H. G.; Patel, Y.; Venkatachalam, M. A., Glomerular filtration of proteins:  
4 679 clearance of anionic, neutral, and cationic horseradish peroxidase in the rat. *Kidney Int* **1978**, *13*  
5 680 (4), 278-88.
- 6 681 39. Itel, F.; Chami, M.; Najer, A.; Lörcher, S.; Wu, D.; Dinu, I. A.; Meier, W., Molecular  
7 682 Organization and Dynamics in Polymersome Membranes: A Lateral Diffusion Study.  
8 683 *Macromolecules* **2014**, *47* (21), 7588-7596.
- 9 684 40. Cao, X.; Chen, C.; Yu, H.; Wang, P., Horseradish peroxidase-encapsulated chitosan  
10 685 nanoparticles for enzyme-prodrug cancer therapy. *Biotechnology letters* **2015**, *37* (1), 81-8.
- 11 686 41. Ihle, S.; Onaca, O.; Rigler, P.; Hauer, B.; Rodríguez-Ropero, F.; Fioroni, M.;  
12 687 Schwaneberg, U., Nanocompartments with a pH release system based on an engineered OmpF  
13 688 channel protein. *Soft Matter* **2011**, *7* (2), 532-539.
- 14 689 42. Nestorovich, E. M.; Rostovtseva, T. K.; Bezrukov, S. M., Residue Ionization and Ion  
15 690 Transport through OmpF Channels. *Biophysical Journal* **2003**, *85* (6), 3718-3729.
- 16 691 43. Phale, P. S.; Philippsen, A.; Kiefhaber, T.; Koebnik, R.; Phale, V. P.; Schirmer, T.;  
17 692 Rosenbusch, J. P., Stability of trimeric OmpF porin: the contributions of the latching loop L2.  
18 693 *Biochemistry* **1998**, *37* (45), 15663-70.
- 19 694 44. Mukherjee, S.; Guptasarma, P., Direct proteolysis-based purification of an overexpressed  
20 695 hyperthermophile protein from Escherichia coli lysate: a novel exploitation of the link between  
21 696 structural stability and proteolytic resistance. *Protein Expression and Purification* **2005**, *40* (1),  
22 697 71-76.
- 23 698 45. Yan, M.; Ge, J.; Liu, Z.; Ouyang, P., Encapsulation of Single Enzyme in Nanogel with  
24 699 Enhanced Biocatalytic Activity and Stability. *Journal of the American Chemical Society* **2006**,  
25 700 *128* (34), 11008-11009.
- 26 701 46. Cecchin, D.; Battaglia, G. In *Protein stabilisation by polymersome entrapment*, **2016**.
- 27 702 47. Critchlow, J. E.; Dunford, H. B., Studies on Horseradish Peroxidase *The Journal of*  
28 703 *Biological Chemistry* **1972**.
- 29 704 48. Mahler, H. R. a.; Baum, H. M. c.; Hübscher, G., Enzymatic oxidation of urate. *Science*  
30 705 **1956**.
- 31 706 49. Moosavi-Movahedi, A. A.; Nazari, K.; Saboury, A. A., Thermodynamics of denaturation  
32 707 of horseradish peroxidase with sodium n-dodecyl sulphate and n-dodecyl trimethylammonium  
33 708 bromide. *Colloids and Surfaces B: Biointerfaces* **1997**, *9* (3), 123-130.
- 34 709 50. Di Risio, S.; Yan, N., Adsorption and inactivation behavior of horseradish peroxidase on  
35 710 cellulosic fiber surfaces. *J Colloid Interface Sci* **2009**, *338* (2), 410-419.
- 36 711 51. Saint, N.; Lou, K. L.; Widmer, C.; Luckey, M.; Schirmer, T.; Rosenbusch, J. P.,  
37 712 Structural and functional characterization of OmpF porin mutants selected for larger pore size. II.  
38 713 Functional characterization. *J Biol Chem* **1996**, *271* (34), 20676-80.
- 39 714 52. Rosenkranz, T.; Katranidis, A.; Atta, D.; Gregor, I.; Enderlein, J.; Grzelakowski, M.;  
40 715 Rigler, P.; Meier, W.; Fitter, J., Observing Proteins as Single Molecules Encapsulated in Surface-  
41 716 Tethered Polymeric Nanocontainers. *ChemBioChem* **2009**, *10* (4), 702-709.
- 42 717 53. Pitts, O. M.; Priest, D. G.; Fish, W. W., Uricase. Subunit composition and resistance to  
43 718 denaturants. *Biochemistry* **1974**, *13* (5), 888-92.
- 44 719 54. Pace, C. N.; Hermans, J., The Stability of Globular Protein. *CRC Critical Reviews in*  
45 720 *Biochemistry* **1975**, *3* (1), 1-43.
- 46 721 55. Achleitner, G.; Gaigg, B.; Krasser, A.; Kainersdorfer, E.; Kohlwein, S. D.; Perktold, A.;  
47 722 Zellnig, G.; Daum, G., Association between the endoplasmic reticulum and mitochondria of

- 1  
2  
3 723 yeast facilitates interorganelle transport of phospholipids through membrane contact. *Eur J*  
4 724 *Biochem* **1999**, *264* (2), 545-53.
- 5 725 56. Barberis, A.; Petrini, E. M.; Mozrzymas, J. W., Impact of synaptic neurotransmitter  
6 726 concentration time course on the kinetics and pharmacological modulation of inhibitory synaptic  
7 727 currents. *Front Cell Neurosci* **2011**, *5*, 6.
- 8 728 57. Francis, K.; Palsson, B. O., Effective intercellular communication distances are  
9 729 determined by the relative time constants for cyto/chemokine secretion and diffusion. *Proc Natl*  
10 730 *Acad Sci U S A* **1997**, *94* (23), 12258-62.
- 11 731 58. Shvartsman, S. Y.; Wiley, H. S.; Deen, W. M.; Lauffenburger, D. A., Spatial range of  
12 732 autocrine signaling: modeling and computational analysis. *Biophys J* **2001**, *81* (4), 1854-67.
- 13 733 59. Chien, A. C.; Hill, N. S.; Levin, P. A., Cell size control in bacteria. *Curr Biol* **2012**, *22*  
14 734 (9), R340-9.
- 15 735 60. Maiuolo, J.; Oppedisano, F.; Gratteri, S.; Muscoli, C.; Mollace, V., Regulation of uric  
16 736 acid metabolism and excretion. *Int J Cardiol* **2016**, *213*, 8-14.
- 17 737 61. Murdoch, C.; Reeves, K. J.; Hearnden, V.; Colley, H.; Massignani, M.; Canton, I.;  
18 738 Madsen, J.; Blanazs, A.; Armes, S. P.; Lewis, A. L.; Macneil, S.; Brown, N. J.; Thornhill, M. H.;  
19 739 Battaglia, G., Internalization and biodistribution of polymersomes into oral squamous cell  
20 740 carcinoma cells in vitro and in vivo. *Nanomedicine* **2010**, *5* (7), 1025-36.

